April 17, 2025

We Want Your Perspective!

Join our roster of respected specialists and share your clinical perspectives.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 14, 2025

HPV Vaccine Reduces Actinic Keratoses

VAXAK randomized trial demonstrates significant reduction in precancerous skin lesions following standard 9-valent alphapapillomavirus vaccination.

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

March 06, 2025

COVID-19 Increases Autoimmune Blistering Disease Risk, Study Finds

COVID-19 infection significantly increases autoimmune blistering disease risk, while vaccination appears protective, researchers report in a study analyzing 112 million patient records

Conexiant

December 16, 2024

FDA Approves Unloxcyt for Skin Cancer

FDA approves Unloxcyt, a new drug by Checkpoint Therapeutics, for the treatment of advanced and metastatic cutaneous squamous cell carcinoma, showing promising results in clinical studies.

Reuters

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant

February 28, 2025

New Study Backs Mohs Surgery for High-Risk cSCC

Mohs surgery was associated with improved outcomes in the treatment of primary high-stage cSCC compared with WLE.

Conexiant